Patient groups, lobbyists pressure CMS to expand Aduhelm coverage

(By Nick Moran for Becker’s Hospital Review)

Following CMS’s preliminary decision to limit the coverage of Biogen’s Alzehimer’s disease treatment Aduhelm, advocates are calling on the agency to broaden its coverage or risk the future of similar drugs, according to a Jan. 17 Politico report. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or

Leave a Reply